natgillin/translations-raw huggingface dataset:
generating a second output signal, the second output signal including a series of voltage spikes resulting from the step of oscillating the input signal and the step of terminating oscillation of the input signal at a rate proportional to the log of the power of the input signal. 
Logaritamski detektor prema bilo kojem od prethodnih zahtjeva, pri čemu funkcionalni element koji prepoznaje i ometa može raditi tako da stvara signal koji ima niz izboja napona koji su posljedica toga što pojačalo započinje oscilaciju, a ometa se oscilacija ulaznog signala brzinom koja je proporcionalna logaritmu snage ulaznog signala.
In certain embodiments, the pharmaceutically effective concentration of PRG4 protein is in a range of 10-10,000 ug/mL, preferably 50-500 ug/mL, and more preferably 100-300 ug/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 10-10,000 ug/mL.
The polymers are used in powder form. 
Polimeri se pogodno primjenjuju kao prah.
The method of claim 24, wherein the disorders and diseases are selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Farmaceutska kompozicija prema patentnom zahtjevu 5, naznačena time što je poremećaj ili bolest izabran/izabrana iz grupe koju čine poremećaji i bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji i bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
The process according to claim 1, wherein the alkaline earth metal carbonate of step a) is a calcium and/or magnesium carbonate. The process according to claim 1, wherein the alkaline earth metal carbonate of step a) is a calcium carbonate. 
Proces prema zahtjevu 1, naznačen time što je karbonat alkalijskog zemnog metala iz koraka a) kalcijev i/ili magnezijev karbonat, i poželjnije kalcijev karbonat kao što je mramor ili dolomit koji sadrže kalcijev karbonat.
The solid formulation according to any of claims 2 to 7, characterized in that the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate, pregelatinised starch and cross-linked polyvinylpyrrolidone. 
Kruti pripravak prema bilo kojem od zahtjeva 2 do 6, naznačen time, da je dezintegrant odabran iz skupine koju čine kroskarmeloza-natrij, natrijev škrobni glikolat, predželatinizirani škrob i križno povezani polivinilpirolidon.
A method of making the tetragonal nano-sized zirconia (ZrO2) is described in the following. 
Metoda priprave tetragonskog cirkonijevog oksida (ZrO2) nano-veličina je sljedeća.
The reception apparatus according to one of claims 9-14, wherein the search space is configured on a data region of a downlink subframe. 
Naprava za prijem sukladno jednom od zahtjeva 5 1li 6, naznačena time da je prostor pretraživanja konfiguriran u podatkovnom predjelu podokvira silazne veze.
The crude product was removed by filtration, re-dissolved in ethyl acetate, and passed through a silica plug to remove any Pd-residues. 
Sirovi produkt se ukloni filtracijom, ponovno otopi u etil acetatu, i propusti kroz silicijevu cijev kako bi se uklonili ostaci Pd.
a housing (12) having a first end (A) at which there is an opening configured for connection to a fluid supply, and a plurality of holes from which a plurality of hollow tubes (16) extend, 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time, da prvi kraj (A) kućišta (12) ima otvor i unutarnju površinu (22) s navojem na otvoru.
and R3 is selected from hydrogen or A method for activating latent reservoirs of HIV comprising administering an effective amount of a phorbol ester of Formula I or a pharmaceutically-acceptable salt thereof to a mammalian subject in need thereof, 
Pripravak za uporabu u prevenciji ili ublažavanju HIV-a u subjekta koji je sisavac, pripravak sadrži učinkovitu količinu forbolskog estera Formule II, ili njegove farmaceutski prikladne soli, izomera, enantiomera, solvata,
A ship as claimed in any one of the preceding claims 5, 9 or 10, characterized in that it comprises a backwashing system (22', 106") for cleaning the semipermeable membrane (7, 7a, 7', 7a', 7", 7a") of the membrane filter (4, 4a, 4', 4a', 4", 4a") of impurity particles, the backwashing system being arranged to feed a fluid free of impurities in a flow direction of the semipermeable membrane (7, 7a, 7', 7a', 7", 7a") of the membrane filter, which is opposite to the flow direction of the purified effluent. 
Brod prema bilo kojem od prethodnih zahtjeva 5, 9 ili 10, naznačen time da sadrži sustav za ispiranje (22', 106") za čišćenje polupropusne membrane (7, 7a, 7', 7a', 7", 7a") membranskog filtera (4, 4a, 4', 4a', 4", 4a") od čestica nečistoća, te je sustav za ispiranje postavljen da dovodi fluid bez nečistoća u smjeru strujanja polupropusne membrane (7, 7a, 7', 7a', 7", 7a") membranskog filtera, koja je suprotna smjeru strujanja pročišćenog efluenta.
The method as claimed in claim 1 or 2 or the antibody for use according to any of claims 3 to 5, in which said tumor-associated antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 29. 
Farmaceutski pripravak radi primjene sukladno zahtjevu 1 ili 2, pri čemu antigen povezan s tumorom ima aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEQ ID NO: 2, 58, 59, 60, 68 i 69.
Use of 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile (Compound I) in the manufacture of a medicament for treating a disease or condition selected from diabetes, cancer, an autoimmune disorder or HIV infection, wherein the medicament is formulated such that Compound I is administered at a weekly dose of between 50 mg and 250 mg, wherein the weekly dose is administered once per week. 
Uporaba 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin- 1-ilmetil]-4-fluoro-benzonitrila (Spoj I), naznačena time što se radi o uporabi za izradu lijeka za liječenje bolesti ili stanja izabranih između dijabetesa, raka, autoimunog poremećaja ili zaraze HIV-om, pri čemu je lijek oblikovan tako da se Spoj I primjenjuje u tjednoj dozi koja iznosi između 50 mg i 250 mg, pri čemu se tjedna doza primjenjuje jednom tjedno.
wherein the anti-PD-1 antibody is for being administered prior to administration of the anti-KIR antibody on Days 1 and 29 and the anti-KIR antibody is for being administered within 30 minutes of the anti-PD-1 antibody. 
(b) gdje anti-PD-1 antitijelo je za administraciju prije administracije anti-KIR antitijela na dane 1 i 29 i anti-KIR antitijelo je za administraciju u okviru 30 minuta anti-PD-1 antitijela.
Y is two amino acid residues, preferably wherein Y is leucine-lysine; and/or X is two amino acid residues, preferably wherein X is aspartate-isoleucine. 
Alkalna fosfataza prema bilo kojem zahtjevu od 1 do 7, naznačena time da a) Yje dva aminokiselinska ostatka, poželjno pri čemu Y je leucin-lizin; i/ili b) Xje dva aminokiselinska ostatka, poželjno pri čemu X je aspartat-izoleucin.
The conjugate of claim 1, wherein said polypeptide is 19 to 50 amino acids in length. 
Konjugat prema zahtjevu 1, naznačen time da je navedeni polipeptid duljine 19 do 50 amino kiselina.
The alcohol-in-oil type emulsion according to any one of claims 1-4, wherein the content of the lower-alcohol phase relative to the total amount of the alcohol-in-oil type emulsion is in the range of 45-95%(w/w), 55-85%(w/w), such as 65-75 %(w/w). 
Emulzija tipa alkohol-u-ulju u skladu s bilo kojim od patentnih zahtjeva 1 do 4, gdje sadržaj niže alkoholne faze u odnosu na ukupnu količinu emulzije tipa alkohol-u-ulju je u rasponu od 45 do 95 % (težinski), 55 do 85 % (težinski), primjerice 65 do 75 % (težinski).
The pharmaceutical composition according to claim 15, wherein the pathological conditions where oxidative stress plays an important role in their pathogenesis are selected from allergies, stroke, Alzheimer's disease, and ischemic cardiovascular diseases. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da su patološka stanja u čijoj patogenezi važnu ulogu ima oksidativan stres odabrana između alergija, udara kapi, Alzheimerove bolesti i ishemijskih kardiovaskularnih bolesti.
a group represented by the following general formula [9]: (wherein * has the same meaning as described above; and RM, RN and RO are the same or different and each represents H, halogen, cyano, alkoxy, carbamoyl, sulfamoyl, monoalkylaminosulfonyl, or alkylsulfonyl, or alternatively two of RM, RN and RO are taken together to represent methylenedioxy), 
[image] (gdje * ima isto značenje kao što je opisano gore; a RM, RN i RO su isti ili različiti i svaki od njih predstavlja H, halogen, cijano, alkoksi, karbamoil, sulfamoil, monoalkilaminosulfonil ili alkilsulfonil, ili se alternativno dva od RM, RN i RO uzima zajedno kako bi predstavljali metilendioksi),
A gas heater according to claim 1, wherein, if none of the thermocouple devices generates electrical current, the electrical current generator does not generate an amount of electrical current of at least said threshold amount, such that the solenoid gas valve is in the closed condition. 
Plinski grijač (10) prema patentnom zahtjevu 1, gdje, ako nijedan od uređaja (30, 32) sa termoparom ne generira električnu struju, generator (28) električne struje ne generira količinu električne struje od najmanje navedene granične količine, tako da je solenoidni ventil za plin u zatvorenom stanju.
The solid dosage form of claim 3, wherein said process comprises spray drying a 4:6 mixture of bardoxolone methyl and a methacrylic acid copolymer. 
Kruti oblik doziranja prema zahtjevu 3, naznačen time da navedeni postupak obuhvaća sušenje raspršivanjem smjese bardoksolon metila i kopolimera metakrilne kiseline u omjeru 4:6.
Method according to claim 1,2 or 3, wherein the pressure of the air introduced into the cavity is controlled to be at least about as high as the air pressure inside the cavity. 
Postupak prema zahtjevu 1, 2 ili 3, gdje se tlak zraka koji se uvodi u šupljinu kontrolira tako da bude visok barem koliko i tlak zraka unutar šupljine.
In this set-up the temperature increase and air convection from the real coil coating conditions could not exactly be copied. 
U tom postavu se porast temperature i zračna konvekcija ne mogu točno kopirati od stvarnih uvjeta prevlake svitka.
about 1 pH unit below the pI of the monoclonal antibody. 
oko 1 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela.
Ar is a phenyl, pyridinyl or thienyl, wherein phenyl, pyridinyl or thienyl is optionally substituted with 1 to 5 R6. 
Ar je fenil, piridinil ili tienil, pri čemu fenil, piridinil ili tienil je opcionalno supstituiran sa 1 do 5 R6.
C—decreased depth of the box X—depth of the storage space for matches for the magnitude of −10<X<=0 mm, at the same time the inside front wall has two extrusion ridges oriented towards the box interior, whereas the outside front wall 8 has a narrowed end folded under towards the box interior. 
X - spremišni prostor za šibice a ujedno unutarnji prednji zid ima dva prijeloma u obliku dva izbočenja, koja se nalaze jedan iznad drugog i usmjereni su prema unutrašnjosti kutije, dok vanjski prednji zid ima suženi kraj presavijen prema unutrašnjosti kutije.
medium exhausting passages for exhausting the vulcanization gas discharged from the interiors of said bladders to an exterior; 
središnje ispušne prolaze (56, 66, 57) za izlazak vulkanizacijskog plina ispuštenog iz unutrašnjosti navedenih mjehura prema van;
introducing into the pluripotent rat cell a large targeting vector (LTVEC) comprising an insert nucleic acid flanked by a 5' homology arm complementary to a first nucleic acid sequence at the genomic locus of interest and a 3' homology arm complementary to a second nucleic acid sequence at the genomic locus of interest, wherein the sum total of the 5' and the 3' homology arms is at least 10 kb; and 
(a) uvođenje u pluripotentnu štakorsku stanicu velikog vektora za ciljanje (LTVEC) koji sadrži ubačenu nukleinsku kiselinu flankiran s 5' homolognim dijelom komplementarno prvoj sekvenci nukleinske kiseline u genomskom lokusu od interesa i 3' homolognim dijelom komplementarno drugoj sekvenci nukleinske kiseline u genomskom lokusu od interesa, pri čemu je ukupan zbroj 5'1 3' homolognih dijelova najmanje 10 kb; i
an inner cup (12) having a generally frusto-conical cup body (22); 
prvi dio (17) koji se smješta unutar unutrašnje čaše (12);
RE3 is selected from a substituent group consisting of hydrogen, lower alkyl optionally substituted by substituent group C, lower alkenyl optionally substituted by substituent group C, lower alkynyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, and heterocycle lower alkyl optionally substituted by substituent group C, 
R'* je odabran iz supstituentske skupine koja se sastoji od sljedećih: vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom €, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C,
The ophthalmic aqueous solution according to any one of claims 1 to 7 wherein the stabilizing agent is selected from the group consisting of ethylenediaminetetraacetic acid and salts thereof, sodium nitrite, ascorbic acid, L-ascorbic acid stearate, sodium hydrogensulfite, alphathioglycerin, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol acetate, potassium dichloroisocyanurate, 2,6-di-t-butyl-4-methylphenol, soybean lecithin, sodium thioglycollate, sodium thiomalate, natural vitamin E, tocopherol, ascorbyl pasthyminate, sodium pyrosulfite, butylhydroxyanisole, 1,3-butylene glycol, pentaerythtyl tetrakis[3-(3,5-di-t-butyl-4-hydroxyphenyl)]propionate, propyl gallate, 2-mercaptobenzimidazole and oxyquinoline sulphate. 
Oftalmološka vodena otopina prema bilo kojem od patentnih zahtjeva 1 do 7, u kojoj je sredstvo za stabilizaciju izabrano iz skupine koju čini etilendiamintetraoctena kiselina i njezine soli, natrij nitrit, askorbinska kiselina, stearat L-askorbinske kiseline, natrij hidrogensulfit, alfatioglicerin, eritorbinska kiselina, cistein hidroklorid, limunska kiselina, tokoferol acetat, kalij dikloroizocijanurat, 2,6-di-t-butil-4-metilfenol, lecitin iz soje, natrij tioglikolat, natrij tiomalat, prirodni vitamin E, tokoferol, askorbil pasthiminat, natrij pirosulfit, butilhidroksianizol, 1,3-butilen glikol, pentaeritil tetrakis[3-(3,5-di-t-butil-4-hidroksifenil)]propionat, propil galat, 2-merkaptobenzimidazol i oksikinolin sulfat.
A compound of Formula (Ia) wherein: 
Formula (ia) naznačen time da:
The crystalline salt form of Claim 3, wherein the x-ray powder diffraction pattern comprises two or more diffraction peaks at 2θ values selected from 14.69±0.20, 16.01±0.20, 21.11±0.20, 22.07±0.20, and 23.18±0.20. 
Kristalni oblik soli u skladu s patentnim zahtjevom 3, naznačen time, da se rendgenska difrakcija u praškastom uzorku sastoji od dvije ili više vršnih vrijednosti na 2θ odabrane od 14.6960.20, 16.0160.20, 21.1160.20, 22.0760.20 i 23.1860.20.
R3a and R11a may be taken together with an adjacent atom to form heterocycle optionally substituted by substituent group D, and 
R* i R''* se mogu dobito zajednički sa susjednim atomom za tvorbu heterocikla koji je prema potrebi supstituiran sa supstituentskom skupinom D, i
Ar is selected from the group consisting of phenyl and thiophen-yl; 
Xi do X, su neovisno odabrani iz skupine koju čine Ci N;
The dihydrotetrabenazine of the invention can be prepared by a process comprising the reaction of a compound of the formula (II): with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter where required separating and isolating a desired dihydrotetrabenazine isomer form. 
Dihidrotetrabenazin izuma se može pripremiti postupkom koji obuhvaća reakciju spoja formule (II): CH,O CH.O s reagensom ili reagensima prikladnima za hidriranje 2,3-dvostruke veze u spoju formule (II) te kasnije kada je to potrebno, odvaja se 1 izolira željeni izomerni oblik dihidrotetrabenazina.
There is a need to mask the taste of such antibiotics in order to ensure patient compliance during therapy. 
Postoji potreba maskiranja okusa takvih antibiotika da bi se osigurala suradljivost pacijenata tijekom terapije.
modelling said borehole equipment by an equivalent computational model for computer simulation, 
modeliranje (31) navedene opreme za bušotine (10) pomoću ekvivalentne komputacijske metode računalne simulacije,
The method of claim 1 wherein the determined number of sequences for differentiating trisomy 21 from euploid cases is at least 120,000 when the biological sample has 20% or more fetal DNA, at least 180,000 when the biological sample has 10% or more fetal DNA, or at least 540,000 when the biological sample has 5% or more fetal DNA. 
Postupak prema zahtjevu 1, naznačen time, da određeni broj sekvenci je barem 120.000 kada biološki uzorak ima 20% ili više fetalnih DNK, najmanje 180.000 kada biološki uzorak ima 10% ili više fetalnih DNK ili najmanje 540.000 kada biološki uzorak ima 5% ili više fetalnih DNK.
A product for the treatment of percolate from waste, comprising a polymer of the superabsorbent polyelectrolytic macromolecular type hydrogel in the dry state, suitable to absorb and retain percolate from waste, and a second component, which is suitable to absorb the gaseous phase produced by the waste, characterized in that, said second component being selected from the group that consists of a-cyclodextrins, B- cyclodextrins, the amount of a-cyclodextrins or B-cyclodextrins being variable between 0 and 20% by weight with respect to the weight of superabsorbent polymer. 
Proizvod za obradu perkolata iz otpada, koji sadrži polimer superapsorbirajućeg polielektrolitičkog makromolekularnog tipa hidrogela u suhom stanju, pogodan za apsorpciju i zadržavanje perkolata iz otpada, i drugu komponentu, koja je pogodna za apsorpciju plinovite faze koja je proizvedena iz otpada, naznačen time što, je navedena druga komponenta odabrana iz skupine koja sadrži a-ciklodekstrine, B-ciklodekstrine, te količine aciklodekstrina ili B-ciklodekstrina variraju između 0 i 20 masenih % odnosu na masu superapsorbirajućeg polimera.
The organic solvent was removed under reduced pressure to obtain 40 g of the title compound as a solid. 
Organsko otapalo je uklonjeno pod sniženim tlakom da bi se dobilo 40 g spoja iz naslova u obliku krutine.
• humanised antibody, and/or 
* humanizirano protutijelo, i/ili
2.5.12, on a titrator Metrohm 7012 KF Titrino. The amount of water in the obtained tablets was 6.0 % by weight, determined by the Karl-Fischer method which was performed according to Ph. Eur. 
2.5.12, na titratoru Metrohm 7012 KF Titrino. Količina vode u dobivenim tabletama bila je 6,0 % masenog udjela, i određena je Karl Fischerovom metodom.
A process for producing a pyrazole compound represented by the formula (I) or its salt: wherein 
Postupak za proizvodnju spoja pirazola predstavljenog formulom (I) ili njegova sol: naznačen time, da
Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, 
Ahl je heteroaril-arilni radikal ili aril-heteroarilni radikal, kojeg čine heteroarilna skupina, koju se bira iz skupine koju čine monociklički 5- ili 6-eročlani heteroarilni radikali, koji sadrže jedan ili dva heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, i arilna skupina, koju se bira iz skupine koju čine fenil 1 naftil, gdje su navedene heteroarilne i arilne skupine vezane zajedno jednostrukom vezom,
dihydroazole compound of formula (I), or a veterinarily or agriculturally acceptable salt thereof: wherein: 
(a) spoj dihidroazola formule (1), ili njegovu veterinarski ili agrikulturno prihvatljivu sol:
the remaining substituents are as defined in claim 1 . 
-C6 alkilamino-karbonilom, i preostali supstituenti su kako je definirano u patentnom zahtjevu 1.
The compound for use according to claim 8, wherein said pathological state is cerebral ischaemia optionally associated with neurodegenerative processes. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je navedeno patološko stanje cerebralna ishemija, izborno povezana s neurodegenerativnim procesima.
wherein said C5 binding motif forms part of a three-helix bundle protein domain, and wherein said C5 binding polypeptide exhibits binding activity to human C5 and to C5 of animal models, such as mouse or rat. 
pri čemu spomenuti motiv za vezanje C5 oblikuje dio proteinske domene troheliksnog svežnja, i pri čemu spomenuti polipeptid koji veže C5 ispoljava aktivnost vezivanja za humani C5 i za C5 u životinjskim modelima, kao što su mišji ili štakorski.
detecting with the processor mechanism at least a third user marking cell on the form (400, 700), wherein the third user marking cell is bounded by at least one indicium that is visible to the camera, and wherein the third user marking cell is detected based at least in part upon at least one of: (a) the displacement vector of the detected first user marking cell; and (b) the displacement vector of the detected second user marking cell. The method of claim 2, further comprising: 
prvi dio u drugoj boji, vidljivoj za najmanje jedan senzor slike, i drugi dio u boji različitoj od druge boje, gdje prvi dio daje potpuni obris drugog dijela, i gdje je omjer između površine koju obuhvaća prvi dio i drugi dio i površine drugog dijela zadan za svaku položajnu oznaku; i gdje se najmanje jedno područje za korisničke oznake detektira uređajem na temelju, u najmanju ruku dijelom:
The organic phase was separated and washed with 3 x 50.0 mL of water. 
Organsku fazu se odvoji 1 ispere s 3 x 50,0 mL vode.
The cover can be manufactured in a light material, such as plastics, which is inexpensive and easy to handle. 
Pokrov se prema predloženom izumu može izraditi iz laganog materijala, kao što je plastika, koja nije skupa i s kojom se lako rukuje.
The dosage form according to embodiment 12, which is adapted for nasal administration. 
Oblik doziranja prema zahtjevu 9, koji je prilagođen za nazalnu primjenu.
The biomaterial as claimed in claim 4, wherein the weight ratio is 25:75. 
Biomaterijali kako su prijavljeni u patentnom zahtjevu 3, naznačeni time da maseni omjer jest 25:75.
The compound as defined above, having the formula IIb: or a tautomer, enantiomer or salt thereof. 
HR P20170404 T1 (VI) ili njegov tautomer, enantiomer ili sol, naznačen time što:
A nucleic acid, encoding a peptide according to any one of Claims 1 to 8. 
Nukleinska kiselina koja se sastoji od niza koji kodira peptid prema Zahtjevu 1. ili 2.
The method of claim 5, wherein the grace period provides a period in addition to the timeslice in which to perform the first function. 
Računalni sustav u skladu s patentnim zahtjevom 4, naznačen time što razdoblje počeka osigurava dodatni period uz odsječak vremena u kojem se provodi prva funkcija.
The compound according to claim 1 having the structure: 
Spoj u skladu sa patentnim zahtjevom 1 koje ima strukturu: [image]